TLDR Androgen deprivation therapy doesn't lower the risk of death from COVID-19 in prostate cancer patients.
The document presents a study analyzing the effect of androgen deprivation therapy (ADT) on the mortality rate of 199 prostate cancer patients who contracted COVID-19. The results showed that 78.4% of the patients were actively using ADT, and 63.3% of the total cohort died from COVID-19. However, the active use of ADT was not found to be a protective factor against death from COVID-19. The study concluded that active use of ADT was not associated with a reduced risk of death in prostate cancer patients with COVID-19, even after adjusting for various factors using propensity score-based pair matching and double robust estimation with inverse weight.
139 citations
,
December 2020 in “Cell Stem Cell” Male hormones affect COVID-19 severity and certain drugs targeting these hormones could help reduce the risk.
113 citations
,
July 2020 in “Communications biology” Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.
134 citations
,
April 2020 in “Journal of Cosmetic Dermatology” Male pattern hair loss could hint at androgens affecting COVID-19 severity.
6 citations
,
January 2024 in “Cancers” Antiandrogens don't help with COVID-19 and aren't recommended.
8 citations
,
December 2022 in “Nature Reviews Endocrinology” Sex hormones' effects on COVID-19 are unclear and more research is needed to understand their potential as treatment.
23 citations
,
September 2021 in “Frontiers in Cellular and Infection Microbiology” Testosterone's effects on COVID-19 are unclear and need more research.
December 2025 in “Current Issues in Molecular Biology” New steroid compounds may help with hormonal therapy and have potential benefits for glucose disorders, but more research is needed.
12 citations
,
August 2020 in “Annals of Oncology” Androgen deprivation therapy might be better for preventing COVID-19 than treating it.
